Summary:
The purpose of this study is to characterize the efficacy and safety of evobrutinib 45 mg administered orally twice daily versus teriflunomide (Aubagio®; 14 mg once a day orally) in participants with relapsing multiple sclerosis (RMS).
Qualified Participants Must:
• Be 18-55 years old
•
Be diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS] or SPMS with relapses)
•
One or more documented relapses within the 2 years before Screening
Additional criteria applies, please contact the site for full details.
Qualified Participants May Receive:
Compensation of up to $4,375 for time, complimentary transportation and meals, no cost study-related treatments and medications.